C. diff causes nearly 30,000 deaths each year in the US, says Ferring, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.
Newer live biotherapeutic products (LBPs) like Rebyota and Vowst offer promising alternatives by delivering purified microbial formulations. Both products have demonstrated efficacy in reducing CDI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback